期刊
JOURNAL OF BIOPHARMACEUTICAL STATISTICS
卷 16, 期 3, 页码 275-283出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/10543400600614742
关键词
Data Monitoring Committee; dose finding; interim analysis; seamless Phase II/ III design; sample size reestimation
A PhRMA Working Group on adaptive clinical trial designs has been formed to investigate and facilitate opportunities for wider acceptance and usage of adaptive designs and related methodologies. A White Paper summarizing the findings of the group is in preparation; this article is an Executive Summary for that full White Paper, and summarizes the findings and recommendations of the group. Logistic, operational, procedural, and statistical challenges associated with adaptive designs are addressed. Three particular areas where it is felt that adaptive designs can be utilized beneficially are discussed: dose finding, seamless Phase II/III trials designs, and sample size reestimation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据